SEARCH

SEARCH BY CITATION

References

  • 1
    Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med 1998;339:17757.
  • 2
    Levine P, Burnham L, Katzin EM, Vogel P. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. JAMA 1941;113:1267.
  • 3
    Mollison PL, Engelfriet CP, Contreras M. Haemolytic disease of the fetus and the newborn. In: MollisonPL, EngelfrietCP, ContrerasM, editors. Blood Transfusion in Clinical Medicine, 10th edn. Oxford: Blackwell Science; 1997. pp. 390424.
  • 4
    Daniels G. Blood group antibodies in haemolytic disease of the fetus and newborn. In: HadlyA, SoothillP, editors. Alloimmune Disorders of Pregnancy. Cambridge: University Press; 2002. pp. 2140.
  • 5
    Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000;14:4461.
  • 6
    Kumpel BM. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 2006;46:16526.
  • 7
    NICE. Routine Antenatal Anti-D Prophylaxis for Women who are Rhesus D Negative. NICE Technology Appraisal Guidance 156. London, UK: National Institute for Health and Clinical Excellence, 2008.
  • 8
    Vandenbussche FPHA, Klumper FJ. [Red cell immunisation and pregnancy]. Dutch Society of Obstetrics and Gynaecoly 2002; clinical guideline [Dutch].
  • 9
    American College of Obstetricans and Gynecologists. ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 1999;66:6370.
  • 10
    Crowther CA, Keirse MJ. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev 2000:CD000020.
  • 11
    Chilcott J, Lloyd JM, Wight J, Forman K, Wray J, Beverley C, et al. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003;7:4.
  • 12
    Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P, et al. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 2004;111:892902.
  • 13
    Engelfriet CP, Reesink HW, Judd WJ, Ulander VM, Kuosmanen M, Koskinen S, et al. Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang 2003;85:32837.
  • 14
    Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, Van der Schoot CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;48:17219.
  • 15
    Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol 1987;156:1548.
  • 16
    Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990;30:34457.
  • 17
    Feldman N, Skoll A, Sibai B. The incidence of significant fetomaternal hemorrhage in patients undergoing cesarean section. Am J Obstet Gynecol 1990;163:8558.
  • 18
    David M, Smidt J, Chen FC, Stein U, Dudenhausen JW. Risk factors for fetal-to-maternal transfusion in Rh D-negative women—results of a prospective study on 942 pregnant women. J Perinat Med 2004;32:2547.
  • 19
    Salim R, Ben Shlomo I, Nachum Z, Mader R, Shalev E. The incidence of large fetomaternal hemorrhage and the Kleihauer–Betke test. Obstet Gynecol 2005;105:103944.
  • 20
    Health Care Insurance Board. Blood Testing in Pregnancy. Pregnancy Immunisation, Hepatitis B and Lues. The Hague: Health Care Insurance Board. National Health Inspection, 1998. [Dutch].
  • 21
    Van der Ploeg CPB, Anthony S, Rijpsta A, Verkerk PH. [Process Monitoring Pre- and Postnatal Screenings 2003]. Leiden, the Netherlands: TNO Quality of Life, 2006. [Dutch].
  • 22
    Koelewijn JM, Vrijkotte TG, Van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008;48:94152.
  • 23
    Murray S, Knox EG, Walker W. Rhesus haemolytic disease of the newborn and the ABO groups. Vox Sang 1965;10:631.
  • 24
    Bais JMJ. Risk selection and detection: a critical appraisal of the Dutch obstetric system. Thesis, Amsterdam: University of Amsterdam, 2004, 25 pp.
  • 25
  • 26
    Ulm B, Svolba G, Ulm MR, Bernaschek G, Panzer S. Male fetuses are particularly affected by maternal alloimmunization to D antigen. Transfusion 1999;39:16973.
  • 27
    Mahboob U, Mazhar SB. Role of Kleihauer test in Rhesus negative pregnancy. J Coll Physicians Surg Pak 2006;16:1203.
  • 28
    Pelikan DM, Scherjon SA, Mesker WE, Groot-Swings GM, Brouwer-Mandema GG, Tanke HJ, et al. Quantification of fetomaternal hemorrhage: a comparative study of the manual and automated microscopic Kleihauer–Betke tests and flow cytometry in clinical samples. Am J Obstet Gynecol 2004;191:5517.
  • 29
    Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’-gestation service program. Can Med Assoc J 1978;118:62730.
  • 30
    Kennedy MS, McNanie J, Waheed A. Detection of anti-D following antepartum injections of Rh immune globulin. Immunohematology 1998;14:13840.
  • 31
    Rudensky B, Mazaki E, Na’amad M, Samueloff A. Lack of anti-D in women at birth following antepartum immune globulin prophylaxis. Eur J Obstet Gynecol Reprod Biol 2003;107:456.
  • 32
    MacKenzie IZ, Roseman F, Findlay J, Thompson K, Jackson E, Scott J, et al. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. BJOG 2006;113:97101.
  • 33
    Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005;45:155460.
  • 34
    Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:115969.
  • 35
    Martins PN, Pratschke J, Pascher A, Fritsche L, Frei U, Neuhaus P, et al. Age and immune response in organ transplantation. Transplantation 2005;79:12732.
  • 36
    MacKenzie I. Antenatal anti-D prophylaxis: one dose or two? BJM 2004;12:134.
  • 37
    MacKenzie IZ, Findlay J, Thompson K, Roseman F. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years. BJOG 2006;113:83943.